Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.

Objective: This study evaluated the eligibility, compliance and persistence of sequential therapy, i.e. a switch to an aromatase inhibitor (AI) following 2-3 years of tamoxifen, in adjuvant endocrine breast cancer (BC) treatment.

Systemic therapy of metastatic breast cancer: the truth beyond the clinical trials.

Objective: To depict a clear and coherent picture of the overall course of palliative treatment in an unselected study cohort over the course of time.

Methods: We compared therapy type and course of 242 women whose distant metastatic disease was diagnosed from 1990 to 2006 and who ultimately died of the disease. We divided the patients into two subgroups depending on the year of diagnosis of metastases (group A: 1998-2006 vs.

Impact of hormone replacement therapy on the histologic subtype of breast cancer.

Objective: Postmenopausal hormone replacement therapy (HRT) is associated with an increase in breast cancer risk, which correlates to the duration of HRT use. We wanted to investigate a possible association between HRT use and the risk of a histologic subtype of breast cancer.

Patients And Methods: From 1995 until 2004, 497 cases of primary ductal, lobular or ductulolobular breast cancer in postmenopausal women were diagnosed at the Department of Gynecology and Obstetrics, University Hospital Basel, Switzerland.

Glypican-3 expression in primary and recurrent ovarian carcinomas.

The identification of glypican-3 (GPC3) expression in malignant neoplasms is potentially of interest because GPC3 might represent a therapeutic target. Tissue microarrays containing tissue cylinders from 308 patients with ovarian carcinomas were used for an immunohistochemical study. There were 255 serous, 38 endometrioid, and 15 clear-cell carcinomas included.

Retroperitoneal displacement of ovary and fallopian tube: a complication of surgical management of incarcerated inguinal hernia in female infants.

Sliding indirect inguinal hernias containing the ipsilateral uterine adnexa are not uncommon in female infants. We report a case of a 12-year-old girl presenting with a benign tumor (serous cystadenofibroma) in a retroperitoneally located ovary. The patient had a history of hernia repair in the neonatal period.

Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features.

Background: The study evaluates characteristics and prognostic significance of breast cancer with histologically proven non-inflammatory skin involvement but without the clinical and histological features that are mandatory for inclusion in the T4 category.

Methods: We compared retrospectively the clinical course of 55 patients with this clinico-pathologic entity to the outcome of a control group of 309 consecutive patients with tumors of the same size but without skin involvement. The median follow-up time was 6.

Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.

Aim: Peroxisome proliferator-activated receptor gamma (PPARgamma) has emerged as a potential therapeutic target in several types of cancer. In ovarian carcinomas, limited and conflicting data on PPARgamma protein expression have been reported.

Methods: The immunoexpression of PPARgamma and its putative target cyclo-oxygenase 2 (COX2) was investigated in tumour tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas after conventional platinum-based chemotherapy.

Epithelial growth factor receptor status in primary and recurrent ovarian cancer.

Success of epidermal growth factor receptor (EGFR) targeting agents in different cancer types is related to EGFR gene mutations and/or copy number gains. We investigated the EGFR gene status and protein expression by DNA mutational analysis, fluorescence in situ hybridization (FISH), and immunohistochemistry in tumor tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas. The patients were classified into six groups with ascending EGFR gene copy numbers.